We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) continues to hit the headlines with its COVID-19 related developments. Recently, the company received the FDA’s Emergency Use Authorization (EUA) for its Amplitude Solution to be used with the TaqPath COVID-19 High-Throughput Combo Kit.
This combination is claimed to enable laboratories to scale up high-sensitivity polymerase chain reaction (PCR) testing.
More on Amplitude and TaqPath
The Amplitude Solution is a molecular diagnostic testing system that helps expand testing capacity by combining Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group. According to Thermo Fisher, this modular system utilizes a high-throughput version of Thermo Fisher's Applied Biosystems TaqPath COVID-19 Combo Kit, which received EUA in March 2020, to process samples in four steps with minimal hands-on time and laboratory space requirements. The kit has multi-gene target design and updated interpretive software, which helps detect SARS-CoV-2 variants.
Thermo Fisher noted that the Amplitude Solution will also allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce and a secured supply of kits, reagents and consumables. The Amplitude Solution has been implemented globally including in labs in Europe and Japan.
A Well-Timed Development
Economic activities are returning to pre-pandemic levels even as emerging variants pose a threat. Though COVID-19 cases are decreasing in some areas owing to vaccine rollouts, the company continues to believe that demand for routine testing will remain strong going forward to control future outbreaks.
For population-wide testing , lab-based PCR tests are suitable, providing confidence in results, capacity to process thousands of samples a day along with consistent and reliable turnaround times.
We believe the latest EUA for the Amplitude Solution to be used with the TaqPath high-throughput is an extremely timely development by Thermo Fisher and expect it to witness accelerared market adoption.
Thermo Fisher's Progress in COVID-19 Testing
Thermo Fisher’s COVID-19 testing revenues have continued to accelerate through the pandemic period as customer demand for sample preparation, PCR solutions and viral transport media remained robust. In response to the pandemic, the company gained regulatory approval to launch the TaqPath COVID-19 combo kit in March, providing gold standard PCR-based test for customers at an unprecedented scale. The company also significantly expanded its portfolio of COVID-19-related products, including Amplitude solution for high-throughput PCR-based testing and TaqCheck PCR test for asymptomatic health surveillance. In addition, it launched a number of advanced products across base business to strengthen leading positions in analytical instruments, biosciences and bioproduction.
According to the company, its COVID-19 testing has reached an unprecedented level, creating a market-leading molecular diagnostics business in just a few months to support hundreds of millions of PCR tests around the world. The company is also actively engaged in projects to help, develop and produce vaccines and therapies. In 2020, this led to $500 million in COVID-19 vaccine therapy revenues and it expects this to increase to $1 billion in 2021.
Share Performance
Thermo Fisher has outperformed its industry in the past six months. The stock has gained 4.4% as against the industry’s 0.8% drop.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Owens & Minor, Inc. (OMI - Free Report) BioRad Laboratories, Inc. (BIO - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Owens & Minor sports a Zacks Rank #1 (Strong Buy), BioRad Laboratories and LeMaitre Vascular carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Owens & Minor has a projected long-term earnings growth rate of 15%.
BioRad Laboratories has a projected long-term earnings growth rate of 7%.
LeMaitre Vascular has an estimated long-term earnings growth rate of 10%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Shutterstock
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
Thermo Fisher Scientific (TMO - Free Report) continues to hit the headlines with its COVID-19 related developments. Recently, the company received the FDA’s Emergency Use Authorization (EUA) for its Amplitude Solution to be used with the TaqPath COVID-19 High-Throughput Combo Kit.
This combination is claimed to enable laboratories to scale up high-sensitivity polymerase chain reaction (PCR) testing.
More on Amplitude and TaqPath
The Amplitude Solution is a molecular diagnostic testing system that helps expand testing capacity by combining Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group. According to Thermo Fisher, this modular system utilizes a high-throughput version of Thermo Fisher's Applied Biosystems TaqPath COVID-19 Combo Kit, which received EUA in March 2020, to process samples in four steps with minimal hands-on time and laboratory space requirements. The kit has multi-gene target design and updated interpretive software, which helps detect SARS-CoV-2 variants.
Thermo Fisher noted that the Amplitude Solution will also allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce and a secured supply of kits, reagents and consumables. The Amplitude Solution has been implemented globally including in labs in Europe and Japan.
A Well-Timed Development
Economic activities are returning to pre-pandemic levels even as emerging variants pose a threat. Though COVID-19 cases are decreasing in some areas owing to vaccine rollouts, the company continues to believe that demand for routine testing will remain strong going forward to control future outbreaks.
For population-wide testing , lab-based PCR tests are suitable, providing confidence in results, capacity to process thousands of samples a day along with consistent and reliable turnaround times.
We believe the latest EUA for the Amplitude Solution to be used with the TaqPath high-throughput is an extremely timely development by Thermo Fisher and expect it to witness accelerared market adoption.
Thermo Fisher's Progress in COVID-19 Testing
Thermo Fisher’s COVID-19 testing revenues have continued to accelerate through the pandemic period as customer demand for sample preparation, PCR solutions and viral transport media remained robust. In response to the pandemic, the company gained regulatory approval to launch the TaqPath COVID-19 combo kit in March, providing gold standard PCR-based test for customers at an unprecedented scale. The company also significantly expanded its portfolio of COVID-19-related products, including Amplitude solution for high-throughput PCR-based testing and TaqCheck PCR test for asymptomatic health surveillance. In addition, it launched a number of advanced products across base business to strengthen leading positions in analytical instruments, biosciences and bioproduction.
According to the company, its COVID-19 testing has reached an unprecedented level, creating a market-leading molecular diagnostics business in just a few months to support hundreds of millions of PCR tests around the world. The company is also actively engaged in projects to help, develop and produce vaccines and therapies. In 2020, this led to $500 million in COVID-19 vaccine therapy revenues and it expects this to increase to $1 billion in 2021.
Share Performance
Thermo Fisher has outperformed its industry in the past six months. The stock has gained 4.4% as against the industry’s 0.8% drop.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Owens & Minor, Inc. (OMI - Free Report) BioRad Laboratories, Inc. (BIO - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Owens & Minor sports a Zacks Rank #1 (Strong Buy), BioRad Laboratories and LeMaitre Vascular carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Owens & Minor has a projected long-term earnings growth rate of 15%.
BioRad Laboratories has a projected long-term earnings growth rate of 7%.
LeMaitre Vascular has an estimated long-term earnings growth rate of 10%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>